


## LISTING OF CLAIMS

This listing of claims will replace all prior versions of claims in the application:

1-29. (Canceled)


30. (New) A method for treating or preventing a disease or disorder associated with suppression of neutrophil apoptosis or excessive release of IL-8, comprising administering an effective amount of a compound selected from the group consisting of:

a) lysophosphatidylcholine (LPC) represented by the following formula I:




wherein  $\text{R}_1$  is an alkyl of  $\text{C}_{4-30}$  or an alkenyl of  $\text{C}_{4-30}$  having one or more double bonds;

b) sphingosylphosphorylcholine (SPC) represented by the following formula II:



- c) ether derivatives of lysophosphatidylcholine (LPC) represented by the following formula III:



wherein  $\text{R}_2$  is an alkyl of  $\text{C}_{4-30}$  or an alkenyl of  $\text{C}_{4-30}$  having one or more double bonds.

31. (New) The method according to Claim 30, wherein lysophosphatidylcholine (LPC) is selected from the group consisting of 1-stearoyl lysophosphatidylcholine, 1-oleoyl lysophosphatidylcholine, 1-myristoyl lysophosphatidylcholine, and 1-palmitoyl lysophosphatidylcholine.

32. (New) The method according to Claim 30, characterized in that said ether derivatives of lysophosphatidylcholine (LPC) are selected from the group consisting of L- $\alpha$ -lysophosphatidylcholine- $\gamma$ -O-alk-1-enyl, L- $\alpha$ -lysophosphatidylcholine- $\gamma$ -O-alkyl, DL- $\alpha$ -lysophosphatidylcholine- $\gamma$ -O-hexadecyl, and L- $\alpha$ -lysophosphatidylcholine- $\gamma$ -O-hexadecyl.

33. (New) The method according to Claim 30, characterized in that said disease is an inflammatory disease.

34. (New) The method according to Claim 33, characterized in that said inflammatory disease is selected from the group consisting of inflammatory bowel disease, peritonitis, osteomyelitis, cellulitis, meningitis, cerebritis, pancreatitis, trauma-inducing shock, bronchial asthma, allergic rhinitis, cystic fibrosis, cerebral apoplexy, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spinal arthropathy, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, juvenile arthropathy, juvenile ankylosing spondylitis, reactive arthropathy, infectious arthritis, post-infectious arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with 'vasculitis syndrome', polyarteritis nodosa, hypersensitivity vasculitis, Wegener's granulomatosis, polymyalgia rheumatica, giant cell arteritis, calcium crystal deposition arthropathy, pseudogout, nonjoint rheumatism, bursitis, tenosynovitis, epicondylitis, neuropathic joint disease, hemarthrosis, Henoch-Schonlein purpura, hypertrophic osteoarthritis, multicentric reticulohistiocytoma, scoliosis, hemochromatosis, hemoglobinopathy, hyperlipoproteinemia, hypogammaglobulinemia, familial mediterranean fever, Gerhardt Disease, systemic lupus erythematosus, relapsing fever, psoriasis, multiple sclerosis, sepsis, septic shock, acute respiratory distress syndrome, multiple organ dysfunction syndrome, chronic obstructive pulmonary disease, rheumatic arthritis, acute lung injury and bronchopulmonary dysplasia.

35. (New) The method according to Claim 30, characterized in that said disease is ischemia reperfusion injury.